InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（6 笔）
内部人交易记录
董事已披露买入
0
已披露卖出
6
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the detailed record of transactions filed by Freund John Gordon, 董事. Director active across 3 companies, notably COLLEGIUM PHARMACEUTICAL, INC. Cumulatively, 17 filings have been recorded. Breakdown: 0 buy · 6 sells. Total volume traded: €3.6m. History available since 20 May 2021. The latest transaction was disclosed on 8 August 2025 (Cession). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Freund John Gordon
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报17 总计
11,659 股@ US$34.363266.0% 占其流量Common StockSEC:0001062993-25-014202:0
12,132 股@ US$15.99065.2% 占其流量Common StockSEC:0001562180-25-005706:0
15,000 股@ US$13.45100.0% 占其流量Common StockSEC:0001062993-25-011425:0
8,675 股0Common StockSEC:0001562180-25-004608:0
9,791 股0Common StockSEC:0001062993-25-009806:0
8,791 股0Common StockSEC:0001562180-24-005334:0
7,693 股0Common StockSEC:0001062993-24-010540:0
30,000 股@ US$20.539910.1% 占其流量Common StockSEC:0001562180-23-006298:0
4,866 股0Common StockSEC:0001562180-23-005109:0
9,792 股0Common StockSEC:0001062993-23-011817:0
8,324 股0Common StockSEC:0001562180-22-005236:0
14,035 股0Common StockSEC:0001062993-22-013302:0
17,990 股@ US$31.280614.4% 占其流量Common StockSEC:0001562180-21-004319:0
3,848 股0Common StockSEC:0001562180-21-004257:0
26,367 股@ US$30.929720.8% 占其流量Common StockSEC:0001562180-21-003880:0
50,827 股@ US$32.540942.1% 占其流量Common StockSEC:0001562180-21-003755:0
9,941 股0Common StockSEC:0001192482-21-000460:0
17 条申报中的 17 条
About Freund John Gordon
Freund John Gordon is Administrateur at SI-BONE, Inc. and Collegium Pharmaceutical, INC, and he was also reported as Director at COLLEGIUM PHARMACEUTICAL, INC. The 17 available filings, all of which are included in the sampled set, cover the period from 2021-05-24 to 2025-08-12, with 0 in purchases and 3557705 in sales, and the largest filings include sales at SI-BONE, Inc. on 2021-05-26 for 1354077.495825849, on 2021-06-01 for 668835.217966624, on 2023-08-11 for 561318.5089830986 and on 2021-06-16 for 464219.4733907477, as well as a sale at Collegium Pharmaceutical, INC on 2025-08-12 for 343112.57798855.
